Boosted by the performance of its new breast-cancer drug Ibrance and children’s vaccine Prevnar, Pfizer reported results well ahead of expectations. Quarterly sales by America’s largest drugmaker were up 20% year-on-year, to $13 billion, with profits of $3 billion. Following an aborted merger with Allergan in April, the firm has said it may split into new- and old-drugs companies.